Sanofi, “We’ll start 2 new Phase III clinical trials of Hanmi’s efpeglenatide this year”
Hanmi Pharm(CEO Sae-Chang Kwon, Jong-Soo Woo) will conduct 2 more new Phase III clinical trials to increase the value of efpeglenatide, a new antidiabetic biologic.
A partnering company of Hanmi Pharm, Sanofi announced this at its 2017 4th quarter performance report on the 7th(local time). Sanof...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
